查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1772235

美國微量殘存疾病檢測市場規模、佔有率、趨勢分析報告（按技術、癌症類型、最終用途、細分市場預測），2025-2033

U.S. Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (Flow Cytometry, PCR, NGS), By Cancer Type (Hematological Malignancy, Solid Tumors), By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

預計 2024 年美國微量殘存疾病檢測市場價值將達到 8.7366 億美元，2025 年至 2033 年期間的複合年成長率為 9.38%。

這是在中國癌症負擔日益加重、醫療體系越來越重視精準醫療的背景下發生的。

根據最近的預測，到2024年，美國將有約89,190人被診斷出患有淋巴瘤，包括何傑金氏病和非何傑金氏病淋巴瘤。預計死亡人數為21,050人，其中非何傑金氏淋巴瘤在男性中更為常見，且死亡率更高。這項令人擔憂的統計數據凸顯了對高靈敏度早期檢測工具的迫切需求，例如MRD檢測。 MRD檢測使醫生能夠在患者治療後，即使病情看似緩解，也能檢測到殘留的癌細胞痕跡。這項技術在識別高復發風險患者、指導進一步治療和改善長期療效方面發揮關鍵作用。

向基於價值的護理和個人化治療方案的轉變，正在將MRD檢測從一種可選的研究工具提升為主流臨床必需品。隨著癌症治療變得更加精準和適應性更強，對MRD檢測等精準疾病監測工具的需求也日益成長。這一趨勢在骨髓惡性腫瘤尤其明顯，MRD狀態在臨床試驗和現實世界治療方案中擴大被用作替代終點。

近年來，次世代定序(NGS) 和流式細胞技術快速發展，提高了 MRD 檢測的準確性、可重複性和臨床實用性。 FDA核准的檢測，例如 Adaptive Biotechnologies 公司用於檢測多發性骨髓瘤、急性淋巴細胞白血病 (ALL) 和慢性淋巴性白血病(CLL) 的 clonoSEQ，為檢測靈敏度和採用率樹立了新的標竿。同樣，Natera 公司 Signatera 是一種基於腫瘤資訊性 ctDNA 的 MRD 檢測，在固體癌管理（包括結直腸癌、乳癌和膀胱癌）中越來越受歡迎。這些檢測可用於長期疾病追蹤、個人化治療決策和早期發現復發。

目錄

第1章調查方法與範圍

第2章美國微量殘存疾病檢測市場：執行摘要

  • 市場概述
  • 技術與服務概覽
  • 癌症類型和最終用途簡介
  • 競爭格局簡介

第3章美國微量殘存疾病檢測市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素分析
    • 造血系統惡性腫瘤發生率和盛行率不斷上升
    • 診斷工具的技術進步
    • 與個人化醫療的整合
  • 市場限制因素分析
    • 先進的 MRD 技術高成本，使用受限
  • 美國微量殘存疾病檢測市場分析工具
    • 產業分析-波特五力分析
    • PESTLE分析

第4章美國的微量殘存疾病檢測：技術評估與趨勢分析

  • 2024 年及 2033 年技術市場佔有率
  • 細分儀表板
  • 美國微量殘存疾病檢測市場技術展望
  • 2021 年至 2033 年市場規模、預測與趨勢分析
    • 流式細胞技術
    • 聚合酵素鏈鎖反應（PCR）
    • 次世代定序（NGS）
    • 其他

第5章美國的微量殘存疾病檢測：癌症類型估計和趨勢分析

  • 2024年及2033年癌症類型市場佔有率
  • 細分儀表板
  • 美國微量殘存疾病檢測市場：癌症類型展望
  • 2021 年至 2033 年市場規模、預測與趨勢分析
    • 造血系統惡性腫瘤
    • 固態腫瘤

第6章微量殘存疾病檢測：最終用途估計與趨勢分析

  • 2024年及2033年最終用途市場佔有率
  • 細分儀表板
  • 美國微量殘存疾病檢測市場前景（依最終用途）
  • 2021 年至 2033 年市場規模、預測與趨勢分析
    • 醫院和專科診所
    • 診斷實驗室
    • 學術研究所
    • 其他

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key Customers
    • Key Company Market Share Analysis, 2024
    • Twist Bioscience
    • Thermo Fisher Scientific, Inc
    • Illumina, Inc.
    • QIAGEN
    • Adaptive Biotechnologies
    • Natera, Inc.
    • Guardant Health
    • Foresight Diagnostics, Inc.
    • NeoGenomics, Inc.
    • Hoffmann-La Roche Ltd.
    • SOPHiA GENETICS
Product Code: GVR-4-68040-651-7

Market Size & Trends:

The U.S. minimal residual disease testing market was estimated at USD 873.66 million in 2024 and is projected to grow at a CAGR of 9.38% from 2025 and 2033, driven by the country's rising cancer burden and the healthcare system's growing emphasis on precision medicine.

According to recent projections, about 89,190 people in the U.S. will be diagnosed with lymphoma in 2024, encompassing both Hodgkin and non-Hodgkin types. An estimated 21,050 deaths are anticipated, with non-Hodgkin lymphoma being both more common and deadlier, especially in men. These alarming statistics underscore the urgent demand for highly sensitive, early detection tools like MRD testing. MRD testing enables physicians to detect trace levels of cancer cells that persist after treatment, even when patients appear to be in remission. This technology plays a vital role in identifying patients at high risk of relapses, guiding further therapy, and improving long-term outcomes.

The shift toward value-based care and personalized treatment plans has elevated MRD testing from an optional research tool to a mainstream clinical necessity. As cancer therapies become more targeted and adaptive, the demand for precise disease monitoring tools like MRD testing continues to grow. This trend is especially pronounced in hematologic malignancies, where MRD status is increasingly being used as a surrogate endpoint in clinical trials and real-world treatment protocols.

Recent years have witnessed rapid advancements in next-generation sequencing (NGS) and flow cytometry, making MRD detection more accurate, reproducible, and clinically actionable. FDA-cleared tests such as Adaptive Biotechnologies' clonoSEQ for multiple myeloma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) have set new benchmarks for test sensitivity and adoption. Similarly, Natera's Signatera, a tumor-informed ctDNA-based MRD test, is gaining traction in solid tumor management, including colorectal, breast, and bladder cancers. These assays allow for longitudinal disease tracking, personalized treatment decisions, and the early detection of recurrence-often months before symptoms or imaging changes appear.

U.S. Minimal Residual Disease Testing Market Report Segmentation

This report forecasts revenue growth at regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. minimal residual disease testing market report based on the technology, cancer type, and end use:

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Next Generation Sequencing (NGS)
    • Amplicon-based NGS
    • Hybridization Capture-based NGS
    • Others
  • Others
  • Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Hematological Malignancy
    • Leukemia
    • Lymphoma
  • Solid Tumors
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Specialty Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Technology Segment
      • 1.1.1.2. Cancer Type Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Primary Sources
  • 1.11. List of Abbreviations

Chapter 2. U.S. Minimal Residual Disease Testing Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Technology and Services Snapshots
  • 2.3. Cancer Type and End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. U.S. Minimal Residual Disease Testing Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising incidence and prevalence of hematological malignancies
    • 3.4.2. Technological advancements in diagnostic tools
    • 3.4.3. Integration with personalized medicines
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost and limited accessibility of advanced MRD technologies
  • 3.6. U.S. Minimal Residual Disease Testing Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat of New Entrants
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTLE Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Technological Landscape
      • 3.6.2.3. Economic Landscape

Chapter 4. U.S. Minimal Residual Disease Testing: Products, Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. U.S. Minimal Residual Disease Testing Market, By Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For The Following
    • 4.4.1. Flow Cytometry
      • 4.4.1.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Polymerase Chain Reaction (PCR)
      • 4.4.2.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Next Generation Sequencing (NGS)
      • 4.4.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
      • 4.4.3.2. Amplicon-based NGS
        • 4.4.3.2.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
      • 4.4.3.3. Hybridization Capture-based NGS
        • 4.4.3.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
      • 4.4.3.4. Others
        • 4.4.3.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Minimal Residual Disease Testing: Cancer Type Estimates & Trend Analysis

  • 5.1. Cancer Type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. U.S. Minimal Residual Disease Testing Market, By Cancer Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For The Following
    • 5.4.1. Hematological Malignancy
      • 5.4.1.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.1.2. Leukemia
        • 5.4.1.2.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
      • 5.4.1.3. Lymphoma
        • 5.4.1.3.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 5.4.2. Solid Tumors
      • 5.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Minimal Residual Disease Testing: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global U.S. Minimal Residual Disease Testing Market, By End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For The Following
    • 6.4.1. Hospitals and Specialty Clinics
      • 6.4.1.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 6.4.2. Diagnostic Laboratories
      • 6.4.2.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 6.4.3. Academic and Research Institutes
    • 6.4.4. Others
      • 6.4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company /Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of Key Distributors and Channel Partners
    • 7.3.2. Key Customers
    • 7.3.3. Key Company Market Share Analysis, 2024
    • 7.3.4. Twist Bioscience
      • 7.3.4.1. Overview
      • 7.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.4.3. Product Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Thermo Fisher Scientific, Inc
      • 7.3.5.1. Overview
      • 7.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.5.3. Product Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. Illumina, Inc.
      • 7.3.6.1. Overview
      • 7.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.6.3. Product Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. QIAGEN
      • 7.3.7.1. Overview
      • 7.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.7.3. Product Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Adaptive Biotechnologies
      • 7.3.8.1. Overview
      • 7.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.8.3. Product Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. Natera, Inc.
      • 7.3.9.1. Overview
      • 7.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.9.3. Product Benchmarking
      • 7.3.9.4. Strategic Initiatives
    • 7.3.10. Guardant Health
      • 7.3.10.1. Overview
      • 7.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.10.3. Product Benchmarking
      • 7.3.10.4. Strategic Initiatives
    • 7.3.11. Foresight Diagnostics, Inc.
      • 7.3.11.1. Overview
      • 7.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.11.3. Product Benchmarking
      • 7.3.11.4. Strategic Initiatives
    • 7.3.12. NeoGenomics, Inc.
      • 7.3.12.1. Overview
      • 7.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.12.3. Product Benchmarking
      • 7.3.12.4. Strategic Initiatives
    • 7.3.13. Hoffmann-La Roche Ltd.
      • 7.3.13.1. Overview
      • 7.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.13.3. Product Benchmarking
      • 7.3.13.4. Strategic Initiatives
    • 7.3.14. SOPHiA GENETICS
      • 7.3.14.1. Overview
      • 7.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.14.3. Product Benchmarking
      • 7.3.14.4. Strategic Initiatives

List of Tables

  • Table 1. List of key distributors and channel partners
  • Table 2. List of key emerging companies'/technology disruptors/innovators
  • Table 3. U.S. Minimal Residual Disease Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 4. U.S. Minimal Residual Disease Testing Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 5. U.S. Minimal Residual Disease Testing Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 U.S. Minimal Residual Disease Testing Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2024
  • Fig. 16 U.S. Minimal Residual Disease Testing Market: Product Movement Analysis
  • Fig. 17 U.S. Minimal Residual Disease Testing Market: Product Outlook and Key Takeaways
  • Fig. 18 Flow Cytometry
  • Fig. 19 Polymerase Chain Reaction (PCR)
  • Fig. 20 Next Generation Sequencing (NGS)
  • Fig. 21 Others Market Estimates and Forecast, 2021 - 2033
  • Fig. 22 Amplicon-based NGS Market Estimates and Forecast, 2021 - 2033
  • Fig. 23 Hybridization Capture-based NGS Market Estimates and Forecast, 2021 - 2033
  • Fig. 24 Other Estimates and Forecast, 2021 - 2033
  • Fig. 25 U.S. Minimal Residual Disease Testing Market: Cancer Type Movement Analysis
  • Fig. 26 U.S. Minimal Residual Disease Testing Market: Cancer Type Outlook and Key Takeaways
  • Fig. 27 Hematological Malignancy Market Estimates and Forecasts, 2021 - 2033
  • Fig. 28 Solid Tumors Market Estimates and Forecasts, 2021 - 2033
  • Fig. 29 Blood & Blood-based Products Market Estimates and Forecasts,2021 - 2033
  • Fig. 30 Leukemia Market Estimates and Forecasts,2021 - 2033
  • Fig. 31 Lymphoma Market Estimates and Forecasts,2021 - 2033
  • Fig. 32 U.S. Minimal Residual Disease Testing Market: End Use Movement Analysis
  • Fig. 33 U.S. Minimal Residual Disease Testing Market: End Use Outlook and Key Takeaways
  • Fig. 34 Hospitals and Specialty Clinics Market Estimates and Forecasts, 2021 - 2033
  • Fig. 35 Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033
  • Fig. 36 Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033
  • Fig. 37 Others Market Estimates and Forecasts, 2021 - 2033